Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Tracon Pharmaceuticals, Inc. (TCON) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/06/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/14/2023 8-K Quarterly results
Docs: "TRACON Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update San Diego, CA – August 14, 2023 – TRACON Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced financial results for the second quarter ended June 30, 2023. The Company will host a conference call and webcast today at 4:30 PM Eastern Time / 1:30 PM Pacific Time. “We were pleased to collect the arbitration award of $22M, the initial net proceeds of which extend our cash runway into early 2024 and past expected full accrual of the ENVASARC pivotal trial,” said Charles Th..."
08/07/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
07/25/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
07/11/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "TRACON Pharmaceuticals Announces Collection of Arbitration Award from I-Mab Biopharma Collection of Award Extends Cash Runway into early 2024 and Past Expected Full Accrual of the ENVASARC Pivotal Trial San Diego, CA – July 11, 2023 – TRACON Pharmaceuticals , a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced it has collected the previously announced arbitration award from I-Mab Biopharma. “We are pleased to collect the award. As we previously announced in April, the net proceeds extend our cash runway into early 2024 and past expected full accrual of the ENVASARC pivotal trial,” said C..."
06/09/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
06/02/2023 8-K Unregistered Sales of Equity Securities  Interactive Data
06/02/2023 SC 13G Lincoln Park Capital Fund, LLC reports a 9% stake in TRACON PHARMACEUTICALS, INC.
06/01/2023 EFFECT Form EFFECT - Notice of Effectiveness:
05/31/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
05/19/2023 S-1 Form S-1 - General form for registration of securities under the Securities Act of 1933:
05/10/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/04/2023 8-K Quarterly results
04/28/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/25/2023 8-K Quarterly results
04/21/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/21/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/21/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/21/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/21/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/21/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/21/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/20/2023 8-K Quarterly results
04/06/2023 8-K Entry into a Material Definitive Agreement  Interactive Data
03/31/2023 8-K Other Events  Interactive Data
03/27/2023 EFFECT Form EFFECT - Notice of Effectiveness:
03/15/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/13/2023 4 Opaleye Management Inc. (10% Owner) has filed a Form 4 on Tracon Pharmaceuticals, Inc.
Txns: Bought 174,508 shares @ $1.38, valued at $240.8k
03/09/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...
Docs: "Form of Pre-Funded Warrant to Purchase Common Stock",
"Securities Purchase Agreement, by and between TRACON Pharmaceuticals, Inc. and the purchaser listed on Exhibit A thereto"
03/08/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
03/08/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/08/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/08/2023 10-K Annual Report for the period ended December 31, 2022
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy